Fig. 1

Re-biopsy timing in patients with ALK mutations receiving different treatment modalities. The inner layer is the proportion of different re-biopsy timing for cohort 1 patients (n = 20). The outer layer is the proportion of different re-biopsy timing for cohort 2 patients (n = 53) in the post-crizotinib stage. During the crizotinib phase in cohort 2, only 1 patient (1.9%) underwent re-biopsy after developing resistance. 2G, second generation; 3G, third generation